UNITED STATES	OMB APPROVAL OMB Number: 3235-0080 Expires: March 31, 2018 Estimated average burden hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number	001-36913
Issuer: KEMPHARM, INC Exchange: The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) Address: 1180 Celebration Boulevard Suite 103 Celebration FLORIDA 34747 Telephone number: (917) 287-3396 (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices) Common Stock (Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1) 17 CFR 240.12d2-2(a)(2) 17 CFR 240.12d2-2(a)(3) 17 CFR 240.12d2-2(a)(4) Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1 Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, The Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2020-08-11 By Aravind Menon Hearings Advisor Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Delisting Determination, The Nasdaq Stock Market, LLC,
August 11, 2020,  KemPharm, Inc. The Nasdaq Stock Market LLC
(the Exchange) has determined to remove from listing the
common stock of KemPharm, Inc. (the Company), effective
at the opening of the trading session on August 21, 2020.
Based on review of information provided by the Company, Nasdaq
Staff determined that the Company no longer qualified for listing
on the Exchange pursuant to Listing Rule 5450(b)(2)(A).
The Company was notified of the Staff determination
on November 15, 2019. The Company appealed the determination
to a Hearing Panel on November 22, 2019. On January 10,
2020, upon review of the information provided by the Company,
the Panel determined to grant the Company request to transfer its
listing to The Nasdaq Capital Market and remain listed on that
market, subject to several milestones. The Panel advised the
Company that May 13, 2020, represented the Panel full discretion
to grant continued listing while the Company remained non
compliant. Subsequently, on March 27, 2020, the Company received
a post hearing delist determination from Nasdaq Staff due to the
Company failure to maintain compliance the with the minimum bid
price requirement as set forth in Listing Rule 5450(a)(1).
On May 18, 2020, the Company informed the Panel that was unable
to regain compliance with the decision requirement.
On May 19, 2020 the Panel issued a final decision denying the
Company continued listing and notified the Company that trading
in the Company securities would be suspended on May 21, 2020.
The Listing Council did not call the matter for review.
The Staff determination to delist the Company became final
on July 6, 2020.